Q4 2024 Cardiff Oncology Inc Earnings Call Transcript
Key Points
- Cardiff Oncology Inc (CRDF) successfully completed a $40 million capital raise, strengthening its financial position.
- The CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC) showed a 64% overall response rate (ORR) in the 30 mg onvansertib arm, compared to 33% in the control arm.
- Onvansertib demonstrated a favorable safety profile, with over 380 patients dosed across multiple trials and the treatment being well tolerated.
- The company strengthened its intellectual property portfolio with a new patent covering the use of onvansertib in combination with bevacizumab for KRAS-mutated mCRC, with an expiration date no earlier than 2043.
- Cardiff Oncology Inc (CRDF) has cash resources expected to provide runway into the first quarter of 2027, ensuring financial stability for ongoing clinical programs.
- The CRDF-004 trial is still in progress, with full enrollment expected in the next few weeks, delaying complete data availability.
- Progression-free survival (PFS) data is not yet mature, and updates are expected beyond the first half of 2025.
- The company faces significant risks and uncertainties inherent in forward-looking statements, which could impact actual results.
- The regulatory pathway for onvansertib's approval is contingent on FDA interactions and may require adjustments based on trial outcomes.
- Competition from other companies, such as Pfizer's BREAKWATER trial, poses challenges in the mCRC treatment landscape.
Welcome to the Cardiff Oncology fourth-quarter 2024 financial results and business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the conference call over to Kiki Patel of Gilmartin Group. Please go ahead.
Thank you, operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander; and Chief Financial Officer, Jamie Levine. During the conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results and timing of data readouts for onvansertib clinical trials.
These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.
Factors that could cause
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
